These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 35014054

  • 1. Tanshinone IIA from Salvia miltiorrhiza exerts anti-fibrotic effects on cardiac fibroblasts and rat heart tissues by suppressing the levels of pro-fibrotic factors: The key role of miR-618.
    Yan N, Xiao C, Wang X, Xu Z, Yang J.
    J Food Biochem; 2022 Feb; 46(2):e14078. PubMed ID: 35014054
    [Abstract] [Full Text] [Related]

  • 2. Tanshinone IIA Ameliorates Progression of CAD Through Regulating Cardiac H9c2 Cells Proliferation and Apoptosis by miR-133a-3p/EGFR Axis.
    Xu H, Li H, Zhu P, Liu Y, Zhou M, Chen A.
    Drug Des Devel Ther; 2020 Feb; 14():2853-2863. PubMed ID: 32764884
    [Abstract] [Full Text] [Related]

  • 3. microRNA-29b Mediates the Antifibrotic Effect of Tanshinone IIA in Postinfarct Cardiac Remodeling.
    Yang F, Li P, Li H, Shi Q, Li S, Zhao L.
    J Cardiovasc Pharmacol; 2015 May; 65(5):456-64. PubMed ID: 25636075
    [Abstract] [Full Text] [Related]

  • 4. Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis.
    Jiang Y, Hu F, Li Q, Shen C, Yang J, Li M.
    Int Immunopharmacol; 2019 Dec; 77():105968. PubMed ID: 31704290
    [Abstract] [Full Text] [Related]

  • 5. A comprehensive review of tanshinone IIA and its derivatives in fibrosis treatment.
    Bi Z, Wang Y, Zhang W.
    Biomed Pharmacother; 2021 May; 137():111404. PubMed ID: 33761617
    [Abstract] [Full Text] [Related]

  • 6. Tanshinone IIA Ameliorates Streptozotocin-Induced Diabetic Nephropathy, Partly by Attenuating PERK Pathway-Induced Fibrosis.
    Xu S, He L, Ding K, Zhang L, Xu X, Wang S, Qian X.
    Drug Des Devel Ther; 2020 May; 14():5773-5782. PubMed ID: 33408464
    [Abstract] [Full Text] [Related]

  • 7. Tanshinone IIA alleviates cardiac hypertrophy through m6A modification of galectin-3.
    Zhang M, Chen Y, Chen H, Shen Y, Pang L, Wu W, Yu Z.
    Bioengineered; 2022 Feb; 13(2):4260-4270. PubMed ID: 35191812
    [Abstract] [Full Text] [Related]

  • 8. Tanshinone ⅡA inhibits homocysteine-induced proliferation of vascular smooth muscle cells via miR-145/CD40 signaling.
    Li Y, Chen F, Guo R, Jia S, Li W, Zhang B.
    Biochem Biophys Res Commun; 2020 Jan 29; 522(1):157-163. PubMed ID: 31757424
    [Abstract] [Full Text] [Related]

  • 9. Tanshinone I attenuates fibrosis in fibrotic kidneys through down-regulation of inhibin beta-A.
    Wu M, Yang F, Huang D, Ye C.
    BMC Complement Med Ther; 2022 Apr 19; 22(1):110. PubMed ID: 35439976
    [Abstract] [Full Text] [Related]

  • 10. Tanshinone IIA improves cardiac function via regulating miR-499-5p dependent angiogenesis in myocardial ischemic mice.
    Wang X, Wu C.
    Microvasc Res; 2022 Sep 19; 143():104399. PubMed ID: 35697130
    [Abstract] [Full Text] [Related]

  • 11. Tanshinone IIA Liposomes Treat Doxorubicin-Induced Glomerulonephritis by Modulating the Microenvironment of Fibrotic Kidneys.
    Dong T, Yang N, Qin J, Zhao C, Gao T, Ma H, Zhu C, Xu H.
    Mol Pharm; 2024 Jul 01; 21(7):3281-3295. PubMed ID: 38848439
    [Abstract] [Full Text] [Related]

  • 12. Activation of SIRT3 by Tanshinone IIA ameliorates renal fibrosis by suppressing the TGF-β/TSP-1 pathway and attenuating oxidative stress.
    Fan Y, Kang S, Shao T, Xu L, Chen J.
    Cell Signal; 2024 Oct 01; 122():111348. PubMed ID: 39153586
    [Abstract] [Full Text] [Related]

  • 13. Tanshinone IIA protects against cardiac fibrosis through inhibition of β-tubulin expression.
    Zhang Y, Zhang S, Chen X.
    J Biol Regul Homeost Agents; 2018 Oct 01; 32(6):1451-1455. PubMed ID: 30574749
    [Abstract] [Full Text] [Related]

  • 14. Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression.
    Ren ZH, Tong YH, Xu W, Ma J, Chen Y.
    Phytomedicine; 2010 Mar 01; 17(3-4):212-8. PubMed ID: 19800776
    [Abstract] [Full Text] [Related]

  • 15. Tanshinone IIA attenuates silica-induced pulmonary fibrosis via inhibition of TGF-β1-Smad signaling pathway.
    Feng F, Li N, Cheng P, Zhang H, Wang H, Wang Y, Wang W.
    Biomed Pharmacother; 2020 Jan 01; 121():109586. PubMed ID: 31706104
    [Abstract] [Full Text] [Related]

  • 16. Tanshinone IIA alleviates acute ethanol-induced myocardial apoptosis mainly through inhibiting the expression of PDCD4 and activating the PI3K/Akt pathway.
    Deng H, Yu B, Li Y.
    Phytother Res; 2021 Aug 01; 35(8):4309-4323. PubMed ID: 34169595
    [Abstract] [Full Text] [Related]

  • 17. Tanshinone IIA alleviates NLRP3 inflammasome-mediated pyroptosis in Mycobacterium tuberculosis-(H37Ra-) infected macrophages by inhibiting endoplasmic reticulum stress.
    Li Y, Fu Y, Sun J, Shen J, Liu F, Ning B, Lu Z, Wei L, Jiang X.
    J Ethnopharmacol; 2022 Jan 10; 282():114595. PubMed ID: 34517060
    [Abstract] [Full Text] [Related]

  • 18. Tanshinone IIA inhibits the adipogenesis and inflammatory response in ox-LDL-challenged human monocyte-derived macrophages via regulating miR-130b/WNT5A.
    Yuan L, Li Q, Zhang Z, Liu Q, Wang X, Fan L.
    J Cell Biochem; 2020 Feb 10; 121(2):1400-1408. PubMed ID: 31512787
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases.
    Guo R, Li L, Su J, Li S, Duncan SE, Liu Z, Fan G.
    Drug Des Devel Ther; 2020 Feb 10; 14():4735-4748. PubMed ID: 33192051
    [Abstract] [Full Text] [Related]

  • 20. The Protective Role of Tanshinone IIA in Silicosis Rat Model via TGF-β1/Smad Signaling Suppression, NOX4 Inhibition and Nrf2/ARE Signaling Activation.
    Feng F, Cheng P, Zhang H, Li N, Qi Y, Wang H, Wang Y, Wang W.
    Drug Des Devel Ther; 2019 Feb 10; 13():4275-4290. PubMed ID: 31908414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.